Matthew Zibelman
Overview
Explore the profile of Matthew Zibelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ged Y, Touma A, Meza Contreras L, Elias R, Van Galen J, Cupo O, et al.
J Immunother
. 2025 Feb;
48(3):113-117.
PMID: 39901604
Metastatic translocation renal cell carcinomas (mtRCCs) are rare and aggressive tumors with limited treatment options. Recent studies demonstrated promising activity of immune-oncology (IO) combinations in mtRCC. However, the effectiveness of...
2.
Chakraborty A, Hasler J, Handorf E, Anari F, Ghatalia P, Miron B, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102218.
PMID: 39388778
Introduction: The ≥3 cycles of neoadjuvant cisplatin-based chemotherapy (NAC) are commonly administered to treat MIBC. However, some patients are unable to complete all planned cycles of NAC. Prognosis of patients...
3.
Zibelman M, Wong V, Reilly J, Zawislak C, Richman D, Keleher C, et al.
Am J Clin Oncol
. 2024 May;
47(9):419-424.
PMID: 38757577
Objectives: The use of immune checkpoint inhibitors (ICIs) as anticancer therapy across a variety of malignancies has led to durable efficacy in a subset of patients. However, associated side effects...
4.
Motzer R, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al.
J Natl Compr Canc Netw
. 2024 Feb;
22(1):4-16.
PMID: 38394781
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic...
5.
Zibelman M, MacFarlane 4th A, Costello K, McGowan T, ONeill J, Kokate R, et al.
Nat Commun
. 2023 Jul;
14(1):4513.
PMID: 37500647
This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-γ) and nivolumab in patients with metastatic solid tumors. Twenty-six patients are treated in four cohorts assessing increasing doses...
6.
Madan R, Bilusic M, Stein M, Donahue R, Arlen P, Karzai F, et al.
Oncologist
. 2023 May;
28(7):642-e561.
PMID: 37134294
Background: Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC. Methods: This was a...
7.
Bukavina L, Isali I, Ginwala R, Sindhani M, Calaway A, Magee D, et al.
Eur Urol Oncol
. 2023 Mar;
6(2):190-203.
PMID: 36868921
Background: The application of next-generation sequencing techniques has enabled characterization of urinary tract microbiome. Although many studies have demonstrated associations between the human microbiome and bladder cancer (BC), these have...
8.
Rudin C, Pandha H, Zibelman M, Akerley W, Harrington K, Day D, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36669791
Background: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. Methods: Patients had advanced non-small cell...
9.
Brown L, Zhu J, Desai K, Kinsey E, Kao C, Lee Y, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36252996
Background: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will...
10.
Pal S, Uzzo R, Karam J, Master V, Donskov F, Suarez C, et al.
Lancet
. 2022 Sep;
400(10358):1103-1116.
PMID: 36099926
Background: The standard of care for locoregional renal cell carcinoma is surgery, but many patients experience recurrence. The objective of the current study was to determine if adjuvant atezolizumab (vs...